

# Elena Obrador Pla

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5236142/elena-obrador-pla-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48  
papers

2,790  
citations

27  
h-index

51  
g-index

51  
ext. papers

3,144  
ext. citations

7.3  
avg, IF

4.72  
L-index

#	Paper	IF	Citations
48	Combination of natural polyphenols with a precursor of NAD <sup>+</sup> and a TLR2/6 ligand lipopeptide protects mice against lethal irradiation. <i>Journal of Advanced Research</i> , <b>2022</b> ,	13	1
47	Nuclear and Radiological Emergencies: Biological Effects, Countermeasures and Biodosimetry. <i>Antioxidants</i> , <b>2022</b> , 11, 1098	7.1	1
46	Pterostilbene in Cancer Therapy. <i>Antioxidants</i> , <b>2021</b> , 10,	7.1	10
45	The Link between Oxidative Stress, Redox Status, Bioenergetics and Mitochondria in the Pathophysiology of ALS. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	15
44	Melanoma in the liver: Oxidative stress and the mechanisms of metastatic cell survival. <i>Seminars in Cancer Biology</i> , <b>2021</b> , 71, 109-121	12.7	2
43	Nicotinamide Riboside and Pterostilbene Cooperatively Delay Motor Neuron Failure in ALS SOD1 Mice. <i>Molecular Neurobiology</i> , <b>2021</b> , 58, 1345-1371	6.2	3
42	NAD Precursors and Antioxidants for the Treatment of Amyotrophic Lateral Sclerosis. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	1
41	Radioprotection and Radiomitigation: From the Bench to Clinical Practice. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	21
40	Oxidative Stress, Neuroinflammation and Mitochondria in the Pathophysiology of Amyotrophic Lateral Sclerosis. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	26
39	Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , <b>2019</b> , 20, 115-122	3.6	36
38	Glucocorticoid receptor antagonism overcomes resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. <i>American Journal of Cancer Research</i> , <b>2019</b> , 9, 2580-2598	4.4	4
37	Changes in Chemokines and Chemokine Receptors Expression in a Mouse Model of Alzheimer's Disease. <i>International Journal of Biological Sciences</i> , <b>2019</b> , 15, 453-463	11.2	15
36	Oxidative stress and antioxidants in the pathophysiology of malignant melanoma. <i>Biological Chemistry</i> , <b>2019</b> , 400, 589-612	4.5	38
35	Neuronal Effects of Sugammadex in combination with Rocuronium or Vecuronium. <i>International Journal of Medical Sciences</i> , <b>2017</b> , 14, 224-230	3.7	5
34	Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 9413-9436	8.3	62
33	Pterostilbene Decreases the Antioxidant Defenses of Aggressive Cancer Cells In Vivo: A Physiological Glucocorticoids- and Nrf2-Dependent Mechanism. <i>Antioxidants and Redox Signaling</i> , <b>2016</b> , 24, 974-90	8.4	37
32	Glutathione in metastases: From mechanisms to clinical applications. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2016</b> , 53, 253-67	9.4	27

31	Effects of Ranolazine on Astrocytes and Neurons in Primary Culture. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150619	3.7	12
30	Astrocytes protect neurons from A $\beta$ -42 peptide-induced neurotoxicity increasing TFAM and PGC-1 and decreasing PPAR- $\gamma$ and SIRT-1. <i>International Journal of Medical Sciences</i> , <b>2015</b> , 12, 48-56	3.7	51
29	WIN 55,212-2, agonist of cannabinoid receptors, prevents amyloid $\beta$ -42 effects on astrocytes in primary culture. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122843	3.7	34
28	Glucocorticoid receptor knockdown decreases the antioxidant protection of B16 melanoma cells: an endocrine system-related mechanism that compromises metastatic cell resistance to vascular endothelium-induced tumor cytotoxicity. <i>PLoS ONE</i> , <b>2014</b> , 9, e96466	3.7	18
27	Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathione-dependent mechanism. <i>Journal of Translational Medicine</i> , <b>2013</b> , 11, 72	8.5	48
26	Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures. <i>International Journal of Medical Sciences</i> , <b>2013</b> , 10, 1278-85	3.7	17
25	Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 8	8.5	11
24	Intertissue flow of glutathione (GSH) as a tumor growth-promoting mechanism: interleukin 6 induces GSH release from hepatocytes in metastatic B16 melanoma-bearing mice. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 15716-27	5.4	21
23	Tumoricidal activity of endothelium-derived NO and the survival of metastatic cells with high GSH and Bcl-2 levels. <i>Nitric Oxide - Biology and Chemistry</i> , <b>2008</b> , 19, 107-14	5	15
22	Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 3330-42	6.1	71
21	Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 2880-90	5.4	31
20	Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2658-66	12.9	62
19	Bcl-2 and Mn-SOD antisense oligodeoxynucleotides and a glutamine-enriched diet facilitate elimination of highly resistant B16 melanoma cells by tumor necrosis factor-alpha and chemotherapy. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 69-79	5.4	38
18	Glutathione in cancer biology and therapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2006</b> , 43, 143-81	5.4	719
17	Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. <i>Neoplasia</i> , <b>2005</b> , 7, 37-47	6.4	121
16	Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 6950-9	5.4	73
15	Down-regulation of glutathione and Bcl-2 synthesis in mouse B16 melanoma cells avoids their survival during interaction with the vascular endothelium. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 39591-9	5.4	41
14	Tumor cytotoxicity by endothelial cells. Impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after in vitro interaction with the hepatic sinusoidal endothelium. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 13888-97	5.4	41

13	Inhibition of cancer growth by resveratrol is related to its low bioavailability. <i>Free Radical Biology and Medicine</i> , <b>2002</b> , 33, 387-98	7.8	300
12	gamma-Glutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. <i>Hepatology</i> , <b>2002</b> , 35, 74-81	11.2	71
11	Glutamine potentiates TNF-alpha-induced tumor cytotoxicity. <i>Free Radical Biology and Medicine</i> , <b>2001</b> , 31, 642-50	7.8	31
10	Tumoricidal activity of endothelial cells. Inhibition of endothelial nitric oxide production abrogates tumor cytotoxicity induced by hepatic sinusoidal endothelium in response to B16 melanoma adhesion in vitro. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 25775-82	5.4	42
9	Possible mechanisms for tumour cell sensitivity to TNF-alpha and potential therapeutic applications. <i>Current Pharmaceutical Biotechnology</i> , <b>2001</b> , 2, 119-30	2.6	15
8	Mitochondrial glutathione depletion by glutamine in growing tumor cells. <i>Free Radical Biology and Medicine</i> , <b>2000</b> , 29, 913-23	7.8	32
7	Growth-associated changes in glutathione content correlate with liver metastatic activity of B16 melanoma cells. <i>Clinical and Experimental Metastasis</i> , <b>1999</b> , 17, 567-74	4.7	77
6	Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. <i>Free Radical Biology and Medicine</i> , <b>1999</b> , 26, 410-8	7.8	155
5	Regulation of tumour cell sensitivity to TNF-induced oxidative stress and cytotoxicity: role of glutathione. <i>BioFactors</i> , <b>1998</b> , 8, 23-6	6.1	22
4	Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature. <i>Hepatology</i> , <b>1998</b> , 27, 1249-56	11.2	54
3	Glutathione and the rate of cellular proliferation determine tumour cell sensitivity to tumour necrosis factor in vivo. <i>Biochemical Journal</i> , <b>1997</b> , 325 ( Pt 1), 183-9	3.8	69
2	Blood glutathione as an index of radiation-induced oxidative stress in mice and humans. <i>Free Radical Biology and Medicine</i> , <b>1997</b> , 22, 1203-9	7.8	127
1	Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. <i>Nature Medicine</i> , <b>1995</b> , 1, 84-8	50.5	66